The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

Early data presented at ASCO annual meeting 2023 shows encouraging responses to treatment in a very difficult to treat patient population Dr. Anthony Kong (Guy’s and St Thomas’ Hospitals, London), Principal Investigator, presented data from ProcemISA, an ongoing clinical trial in anti-PD1…